Turkey Pharmaceuticals and Healthcare Report Q4 2017
Turkey presents significant growth opportunities for multinational pharmaceutical firms, onaccount of its large, ageing population with a high and rapidly growing prevalence of non-communicablediseases. However, the country's regulatory environment and government's pharmaceutical policies willdeter innovative drugmakers, while the weakness of the lira will erode revenues. Nevertheless, the countryremains a key market in the region.
Headline Expenditure Projections
Pharmaceuticals: TRY28.64bn (USD9.47bn) in 2016 to TRY31.59bn (USD9.06bn) in 2017; +10.3% inlocal currency and -4.3% US dollar terms. Forecast unchanged from previous quarter.
Healthcare: TRY117.08bn (USD38.71bn) in 2016 to TRY132.07bn (USD37.88bn) in 2016; +12.8% inlocal currency and -2.2% US dollar terms. Forecast revised downward from previous quarter.